Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 2000, p. 3097-3100, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Simultaneous Quantitation of Intracellular
Zidovudine and Lamivudine Triphosphates in Human Immunodeficiency
Virus-Infected Individuals
Jose F.
Rodriguez,1,2,*
Jorge L.
Rodriguez,1
Jorge
Santana,3
Hermes
García,4 and
Osvaldo
Rosario2
Department of
Biochemistry1 and Department of
Medicine,3 School of Medicine, Medical Sciences
Campus, University of Puerto Rico, and Puerto Rico Health
Department (CLETS),4 San Juan, and
Department of Chemistry, Rio Piedras Campus, University of
Puerto Rico, Rio Piedras,2 Puerto Rico
Received 11 February 2000/Returned for modification 28 May
2000/Accepted 21 August 2000
Highly active antiretroviral therapy (HAART) is the standard
treatment for infection with human immunodeficiency virus (HIV). The
most common HAART regimen consists of the combination of at least one
protease inhibitor (PI) with two nucleoside reverse transcriptase
inhibitors (NRTIs). Contrary to PIs, NRTIs require intracellular
activation from the parent compound of their triphosphate moiety to
suppress HIV replication. Simultaneous intracellular determination of
two NRTI triphosphates is difficult to accomplish due to their
relatively small concentrations in peripheral blood mononuclear cells
(PBMCs), requiring large amounts of blood from HIV-positive patients.
Recently, we described a method to determine intracellular zidovudine
triphosphate (ZDV-TP) concentrations in HIV-infected patients by using
solid-phase extraction and tandem mass spectrometry. The limit of
quantitation (LOQ) for ZDV-TP was 0.10 pmol, and the method was
successfully used for the determination of ZDV-TP in HIV-positive
patients. In this study, we enhanced the aforementioned method by the
simultaneous quantitation of ZDV-TP and lamivudine triphosphate
(3TC-TP) in PBMCs from HIV-infected patients. The LOQ for 3TC-TP was
4.0 pmol, with an interassay coefficient of variation and an accuracy
of 7 and 12%, respectively. This method was successfully applied to
the simultaneous in vivo determination of the ZDV-TP and 3TC-TP
pharmacokinetic profiles from HIV-infected patients receiving HAART.
*
Corresponding author. Mailing address: Department of
Biochemistry, P.O. Box 365067, School of Medicine, Medical Sciences
Campus, University of Puerto Rico, San Juan Puerto Rico 00936-5067. Phone and Fax: (787) 754-4929. E-mail:
j_rodriguez{at}rcmaxp.upr.clu.edu.
Antimicrobial Agents and Chemotherapy, November 2000, p. 3097-3100, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F.
(2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother.
52: 4241-4250
[Abstract]
[Full Text]
-
Flynn, P. M., Rodman, J., Lindsey, J. C., Robbins, B., Capparelli, E., Knapp, K. M., Rodriguez, J. F., McNamara, J., Serchuck, L., Heckman, B., Martinez, J., the PACTG P1012 Team,
(2007). Intracellular Pharmacokinetics of Once versus Twice Daily Zidovudine and Lamivudine in Adolescents. Antimicrob. Agents Chemother.
51: 3516-3522
[Abstract]
[Full Text]
-
Benech, H., Becher, F., Pruvost, A., Grassi, J. J., Melendez, M., Rodriguez, J. F.
(2006). Is Stavudine triphosphate a natural metabolite of Zidovudine?. Antimicrob. Agents Chemother.
50: 2899-2901
[Full Text]
-
Melendez, M., Blanco, R., Delgado, W., Garcia, R., Santana, J., Garcia, H., Rosario, O., Rodriguez, J. F.
(2006). Lack of Evidence for In Vivo Transformation of Zidovudine Triphosphate to Stavudine Triphosphate in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother.
50: 835-840
[Abstract]
[Full Text]
-
Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., Dieterich, D., Wang, K., Gries, J.-M., Hoggard, P. G., Back, D., for the APRICOT Study Group,
(2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrob. Agents Chemother.
49: 3997-4008
[Abstract]
[Full Text]
-
Le Saint, C., Terreux, R., Duval, D., Durant, J., Ettesse, H., Dellamonica, P., Guedj, R., Vincent, J. P., Cupo, A.
(2004). Determination of ddATP Levels in Human Immunodeficiency Virus-Infected Patients Treated with Dideoxyinosine. Antimicrob. Agents Chemother.
48: 589-595
[Abstract]
[Full Text]
-
Quan, Y., Brenner, B. G., Oliveira, M., Wainberg, M. A.
(2003). Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V Mutation. Antimicrob. Agents Chemother.
47: 747-754
[Abstract]
[Full Text]
-
Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., Khoo, S. H., Back, D. J.
(2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother.
47: 255-261
[Abstract]
[Full Text]
-
Schinazi, R. F., Mellors, J., Bazmi, H., Diamond, S., Garber, S., Gallagher, K., Geleziunas, R., Klabe, R., Pierce, M., Rayner, M., Wu, J.-T., Zhang, H., Hammond, J., Bacheler, L., Manion, D. J., Otto, M. J., Stuyver, L., Trainor, G., Liotta, D. C., Erickson-Viitanen, S.
(2002). DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants. Antimicrob. Agents Chemother.
46: 1394-1401
[Abstract]
[Full Text]
-
Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., Back, D. J.
(2002). Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother.
46: 135-143
[Abstract]
[Full Text]